Literature DB >> 26246568

Topography of the Human Papillomavirus Minor Capsid Protein L2 during Vesicular Trafficking of Infectious Entry.

Stephen DiGiuseppe1, Timothy R Keiffer1, Malgorzata Bienkowska-Haba1, Wioleta Luszczek1, Lucile G M Guion1, Martin Müller2, Martin Sapp3.   

Abstract

UNLABELLED: The human papillomavirus (HPV) capsid is composed of the major capsid protein L1 and the minor capsid protein L2. During entry, the HPV capsid undergoes numerous conformational changes that result in endosomal uptake and subsequent trafficking of the L2 protein in complex with the viral DNA to the trans-Golgi network. To facilitate this transport, the L2 protein harbors a number of putative motifs that, if capable of direct interaction, would interact with cytosolic host cell factors. These data imply that a portion of L2 becomes cytosolic during infection. Using a low concentration of digitonin to selectively permeabilize the plasma membrane of infected cells, we mapped the topography of the L2 protein during infection. We observed that epitopes within amino acid residues 64 to 81 and 163 to 170 and a C-terminal tag of HPV16 L2 are exposed on the cytosolic side of intracellular membranes, whereas an epitope within residues 20 to 38, which are upstream of a putative transmembrane region, is luminal. Corroborating these findings, we also found that L2 protein is sensitive to trypsin digestion during infection. These data demonstrate that the majority of the L2 protein becomes accessible on the cytosolic side of intracellular membranes in order to interact with cytosolic factors to facilitate vesicular trafficking. IMPORTANCE: In order to complete infectious entry, nonenveloped viruses have to pass cellular membranes. This is often achieved through the viral capsid protein associating with or integrating into intracellular membrane. Here, we determine the topography of HPV L2 protein in the endocytic vesicular compartment, suggesting that L2 becomes a transmembrane protein with a short luminal portion and with the majority facing the cytosolic side for interaction with host cell transport factors.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26246568      PMCID: PMC4580179          DOI: 10.1128/JVI.01588-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.

Authors:  Ivonne Rubio; Hanna Seitz; Elena Canali; Peter Sehr; Angelo Bolchi; Massimo Tommasino; Simone Ottonello; Martin Müller
Journal:  Virology       Date:  2010-11-11       Impact factor: 3.616

2.  HPV: The global burden.

Authors:  James Mitchell Crow
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

3.  Role of endosomes in simian virus 40 entry and infection.

Authors:  Sabrina Engel; Thomas Heger; Roberta Mancini; Fabian Herzog; Jürgen Kartenbeck; Arnold Hayer; Ari Helenius
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

4.  Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17.

Authors:  Martina Bergant Marušič; Michelle A Ozbun; Samuel K Campos; Michael P Myers; Lawrence Banks
Journal:  Traffic       Date:  2012-01-08       Impact factor: 6.215

5.  Identification of the dynein light chains required for human papillomavirus infection.

Authors:  Marc A Schneider; Gilles A Spoden; Luise Florin; Carsten Lambert
Journal:  Cell Microbiol       Date:  2011-01       Impact factor: 3.715

Review 6.  Global burden of human papillomavirus and related diseases.

Authors:  David Forman; Catherine de Martel; Charles J Lacey; Isabelle Soerjomataram; Joannie Lortet-Tieulent; Laia Bruni; Jerome Vignat; Jacques Ferlay; Freddie Bray; Martyn Plummer; Silvia Franceschi
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

7.  A large and intact viral particle penetrates the endoplasmic reticulum membrane to reach the cytosol.

Authors:  Takamasa Inoue; Billy Tsai
Journal:  PLoS Pathog       Date:  2011-05-12       Impact factor: 6.823

8.  Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections.

Authors:  Zurab Surviladze; Agnieszka Dziduszko; Michelle A Ozbun
Journal:  PLoS Pathog       Date:  2012-02-09       Impact factor: 6.823

9.  Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis.

Authors:  Mario Schelhaas; Bhavin Shah; Michael Holzer; Peter Blattmann; Lena Kühling; Patricia M Day; John T Schiller; Ari Helenius
Journal:  PLoS Pathog       Date:  2012-04-19       Impact factor: 6.823

10.  Direct binding of retromer to human papillomavirus type 16 minor capsid protein L2 mediates endosome exit during viral infection.

Authors:  Andreea Popa; Wei Zhang; Megan S Harrison; Kylia Goodner; Teymur Kazakov; Edward C Goodwin; Alex Lipovsky; Christopher G Burd; Daniel DiMaio
Journal:  PLoS Pathog       Date:  2015-02-18       Impact factor: 6.823

View more
  35 in total

Review 1.  Cruising the cellular highways: How human papillomavirus travels from the surface to the nucleus.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G Guion; Martin Sapp
Journal:  Virus Res       Date:  2016-10-29       Impact factor: 3.303

Review 2.  Human Papillomavirus Entry: Hiding in a Bubble.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Martin Sapp
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

3.  Incoming human papillomavirus type 16 genome resides in a vesicular compartment throughout mitosis.

Authors:  Stephen DiGiuseppe; Wioleta Luszczek; Timothy R Keiffer; Malgorzata Bienkowska-Haba; Lucile G M Guion; Martin J Sapp
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-17       Impact factor: 11.205

4.  Human Papillomavirus 16 Infection Induces VAP-Dependent Endosomal Tubulation.

Authors:  Abida Siddiqa; Paola Massimi; David Pim; Justyna Broniarczyk; Lawrence Banks
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

5.  Human Papillomavirus infection requires the CCT Chaperonin Complex.

Authors:  Marina Bugnon Valdano; Paola Massimi; Justyna Broniarczyk; David Pim; Michael Myers; Daniela Gardiol; Lawrence Banks
Journal:  J Virol       Date:  2021-03-17       Impact factor: 5.103

6.  Cell-Penetrating Peptide Mediates Intracellular Membrane Passage of Human Papillomavirus L2 Protein to Trigger Retrograde Trafficking.

Authors:  Pengwei Zhang; Gabriel Monteiro da Silva; Catherine Deatherage; Christopher Burd; Daniel DiMaio
Journal:  Cell       Date:  2018-08-16       Impact factor: 41.582

7.  Incoming human papillomavirus 16 genome is lost in PML protein-deficient HaCaT keratinocytes.

Authors:  Malgorzata Bienkowska-Haba; Wioleta Luszczek; Timothy R Keiffer; Lucile G M Guion; Stephen DiGiuseppe; Rona S Scott; Martin Sapp
Journal:  Cell Microbiol       Date:  2017-01-23       Impact factor: 3.715

8.  Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G M Guion; Timothy R Keiffer; Martin Sapp
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

9.  Infectious Bursal Disease Virus Hijacks Endosomal Membranes as the Scaffolding Structure for Viral Replication.

Authors:  María Cecilia Gimenez; Flavia Adriana Zanetti; Mauricio R Terebiznik; María Isabel Colombo; Laura Ruth Delgui
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

10.  The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis.

Authors:  Elena Wüstenhagen; Laura Hampe; Fatima Boukhallouk; Marc A Schneider; Gilles A Spoden; Inka Negwer; Kaloian Koynov; W Martin Kast; Luise Florin
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.